Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM)

Background. The combination of chemotherapy plus anti HER-2 agents is the mainstay of HER-2 positive advanced breast cancer (ABC) therapy. We conducted a phase II trial testing activity and safety of trastuzumab and metronomic capecitabine/cyclophosphamide (HEX) as first-line therapy in HER-2 positi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Breast
Autors principals: Orlando, Laura, Lorusso, Vito, Giotta, Francesco, Di Maio, Massimo, Schiavone, Paola, Fedele, Palma, Quaranta, Annamaria, Caliolo, Chiara, Ciccarese, Mariangela, Cinefra, Margherita, Romito, Sante, Pisconti, Salvatore, Prete, Salvatore del, Aieta, Michele, Rizzi, Daniele, Maiello, Evaristo, Colucci, Giuseppe, Cinieri, Saverio
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2020
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7375616/
https://ncbi.nlm.nih.gov/pubmed/32540553
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.breast.2020.06.002
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars